IL6, rIL-6R and general alkaline phosphotase activity in bone tumors and their role in the prognosis of disease

The comparative analysis of IL-6, rIL-6R levels and of general AP activity in blood serum of 159 patients with different malignant and benign bone tumors was carried out. Medians of serum IL-6 levels were found significantly higher in bone sarcomas (5,3 pg/ml), benign tumors (3,2 pg/ml) and also in giant cell tumors (GCT) (3,9 pg/ml) than in control group (1,2 pg/ml, p=0,0001). The highest IL-6 levels were observed in malignant fibrous histiocytomas (MFH) and also in Ewing's sarcomas. As for IL-6 receptors, no differences were observed in rIL-6R levels among bone sarcomas, benign bone tumors and also GCT. The reverse correspondence between initial rIL-6R serum levels (before treatment), treatment pathomorphosis and malignancy level were demonstrated in EwS and OS. rIL-6R serum levels correlated positively with tumor size (T) especially in chondrosarcomas (ChS). Also the positive correlation was shown between general AP activity and both of tumor size and metastasizing (p=0,02) and additionally malignancy level in patients with bone sarcomas. Reliable differences were found in AP serum activity between benign and malignant bone neoplasms. Combination of IL-6 level and of general AP activity was evaluated as the most significant for relapse-free survival prognosis in patients with bone sarcomas by multifactor analysis.

IL-6, rIL-6R, AP, prognosis, bone sarcomas, blood serum

1. Алиев М.Д. Первичные злокачественные опухоли костей. М.,РОНЦ. 2008,408 с.

2. Кушлинский Н.Е., Бабкина И.В., Соловьев Ю.Н., Алиев М.Д., Тарасова Т.А., Трапезников H.H. Интерлейкин-6 в сыворотке крови больных новообразованиями костей. Кремлевская медицина. 2001, № 4, с. 62-64.

3. Мачак Г.Н., Кочергина Н.В., Сенько О.В., Кузнецова А.В. Клинико-рентгенологические критерии оценки риска на фоне предоперационной химиотерапии остеосаркомы. Вопросы онкологии. 2005, т. 51, № 3, с. 322-327.

4. Соловьев Ю.Н. Опухоли и опухолеподобные поражения скелета (опыт изучения 4899 наблюдений). Вестник ОНЦ РАМН. 1998, № 1,с. 13-18.

5. Соловьев Ю.Н. Опухоли костей: классификация, номенклатура, проблемы диагностики. Архив патологии. 2003, т. 65, № 5, с. 3-6.

6. Трапезников H.H., Алиев М.Д., Мачак Г.Н. и соавт. Лечение остеосаркомы конечностей на рубеже столетий (полувековой опыт исследований). Вестник РАМН. 2001, № 9, с. 46-49.

7. Тупицын H.H. Фундаментальные вопросы регуляции опухолевого роста, опосредованного рецепторным комплексом интерлейкина-6. В материалах IV Российской онкологическойконференции. М., 2000, с. 209-214.

8. Blanchard F., Duplomb L., Baud'huin M., Brounais В. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Crowth Factor Rev. 2009, v. 20, No. 1, p. 19-28.

9. Folpe A.L., Inwards C.Y. Bone and soft tissue pathology (A volume in the series foundations in diagnostic pathology. Series editor: J.R. Goldblum) SAUNDERS Elsevier, Philadelphia. 2010, 462 p.

10. Narazaki M., Yasukawa K., Saito T. et al. Soluble forms of the interleukin-6 signal-transducing receptor component gpl30 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood J. 1993, v. 82, p. 1120-1126.

11. Rutkowski P., Kaminska J., Kowalska M., Ruka W., Steifen J. Cytokine and cytokine receptor serum levels in adult bone sarcome patients: correlations with local tumor extent and prognosis. J. Surg. Oncol. 2003, v. 84, p. 151-159.

12. Weinberg R.A. The biology of cancer. New York: Garland Science. 2007.

13. Yamasaki K., Taga T., Hirata Y. et al. Cloning and expression of the human interleukin-6 (B2/INFbeta 2) receptor. Science. 1998, v. 241, p. 825-828.

14. Yasukawa K., Hirano T., Watakabe Y. et al. Structure and expression of human В-cell stimulatory factor - 2 (BSF-2/ I16) gene. EMBO J. 1987, v. 6, No. 10, p. 2939-2945.